NCT06980038 2026-04-16
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
13 trialsNCT06172296 2026-04-14
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06805305 2026-04-14
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Diakonos Oncology Corporation
Phase 2 Recruiting
NCT07288112 2026-04-14
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
Diakonos Oncology Corporation
Phase 1/2 Recruiting
NCT07061964 2026-04-13
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07000084 2026-04-07
GAIN-BCG
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06914479 2026-03-11
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
University of Michigan Rogel Cancer Center
Phase 1 Recruiting
NCT06470282 2026-02-18
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
University of California, San Francisco
Phase 1/2 Recruiting
NCT07227961 2025-11-13
PROMIS and Mobility Evaluation in Sarcoma Patients
University of Calgary
Recruiting
NCT06537154 2025-07-30
NEO-BLAST
University of British Columbia
Phase 2/3 Recruiting
NCT07067749 2025-07-24
TEMPO-MIBC
University of Rome Tor Vergata
Phase 3 Recruiting
NCT06146725 2023-11-27
RESBIOP
Erasmus Medical Center
Recruiting
NCT06146738 2023-11-27
PALSUR
Erasmus Medical Center
Recruiting